Newsletter
Harm Reduction’s Road From Fringe to Federal Drug Policy

Tradeoffs

Harm Reduction’s Road From Fringe to Federal Drug Policy

January 27, 2022

Harm Reduction’s Road From Fringe to Federal Drug Policy

The overdose crisis in the U.S. is as deadly as it’s ever been. In response, the Biden administration is embracing a controversial strategy known as harm reduction, which seeks to keep drug users safe even as they continue using. We explore how harm reduction has become more mainstream and what kind of impact we can expect it to have on the overdose crisis.

Guests:

Ricky Bluthenthal, PhD, Associate Dean for Social Justice; Keck School of Medicine, University of Southern California

Keith Humphreys, PhD, Esther Ting Memorial Professor of Psychiatry and Behavioral Services, Stanford University

Beau Kilmer, PhD, Director of the RAND Drug Policy Research Center

Kimberly Sue, MD, PhD, Assistant Professor of Medicine, Yale School of Medicine

Maia Szalavitz, Journalist and Author, Undoing Drugs: The Untold Story of Harm Reduction and the Future of Addiction

Read a full transcript and dig deeper into the issues explored in today’s episode on our website.

Support this type of journalism today by making a donation.

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff.

Follow us on Twitter.


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

Proudly supported by:

cover
What Will Variant Sigma Look Like? with Michael T. Osterholm, Ph.D., Regents Professor, Division of Environmental Health Science; Director, Center for Infectious Disease Research and Policy (CIDRAP) University of Minnesota